UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
77-0192527
|
(State or other jurisdiction of
incorporation or organization) |
(I.R.S. Employer
Identification Number) |
3760 Rocky Mountain Avenue
Loveland, Colorado |
80538
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant's telephone number, including area code:
(970) 493-7272
|
Large accelerated filer
o
|
Accelerated filer
x
|
Non-accelerated filer
o
(Do not check if a small reporting company)
|
Small Reporting Company
¨
|
Emerging growth company
o
|
|
|
|
|
Page
|
PART I - FINANCIAL INFORMATION
|
|
||
|
Item 1.
|
Unaudited Condensed Consolidated Financial Statements:
|
|
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
Item 2.
|
||
|
Item 3.
|
||
|
Item 4.
|
||
PART II - OTHER INFORMATION
|
|
||
|
Item 1.
|
||
|
Item 1A.
|
||
|
Item 2.
|
||
|
Item 3.
|
||
|
Item 4.
|
||
|
Item 5.
|
||
|
Item 6.
|
||
|
|
||
|
|
|
June 30,
|
|
December 31,
|
||||
|
|
2017
|
|
2016
|
||||
|
|
(unaudited)
|
|
|
||||
ASSETS
|
||||||||
Current assets:
|
|
|
|
|
|
|
||
Cash and cash equivalents
|
|
$
|
3,727
|
|
|
$
|
10,794
|
|
Accounts receivable, net of allowance for doubtful accounts of
$267 and $237, respectively |
|
14,459
|
|
|
20,857
|
|
||
Due from – related parties
|
|
21
|
|
|
100
|
|
||
Inventories, net
|
|
26,068
|
|
|
20,395
|
|
||
Other current assets
|
|
3,713
|
|
|
3,127
|
|
||
Total current assets
|
|
47,988
|
|
|
55,273
|
|
||
Property and equipment, net
|
|
16,159
|
|
|
16,581
|
|
||
Goodwill
|
|
26,706
|
|
|
26,647
|
|
||
Other intangible assets, net
|
|
2,152
|
|
|
2,346
|
|
||
Deferred tax asset, net
|
|
21,052
|
|
|
21,122
|
|
||
Other non-current assets
|
|
12,352
|
|
|
8,875
|
|
||
Total assets
|
|
$
|
126,409
|
|
|
$
|
130,844
|
|
|
|
|
|
|
||||
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
Current liabilities:
|
|
|
|
|
|
|
||
Accounts payable
|
|
$
|
7,410
|
|
|
$
|
7,154
|
|
Accrued liabilities
|
|
4,668
|
|
|
6,469
|
|
||
Current portion of deferred revenue
|
|
3,424
|
|
|
3,439
|
|
||
Obligation to purchase minority interest
|
|
—
|
|
|
14,602
|
|
||
Line of credit and other short-term borrowings
|
|
4,033
|
|
|
750
|
|
||
Total current liabilities
|
|
19,535
|
|
|
32,414
|
|
||
Deferred revenue, net of current portion, and other
|
|
10,299
|
|
|
11,455
|
|
||
Total liabilities
|
|
29,834
|
|
|
43,869
|
|
||
Commitments and contingencies (Note 11)
|
|
|
|
|
|
|
||
Stockholders' equity:
|
|
|
|
|
|
|
||
Preferred stock, $.01 par value, 2,500,000 shares authorized,
none issued or outstanding |
|
—
|
|
|
—
|
|
||
Traditional common stock, $.01 par value, 10,000,000 shares authorized,
none issued or outstanding |
|
—
|
|
|
—
|
|
||
Public common stock, $.01 par value, 10,000,000 shares authorized,
7,195,623 and 7,026,051 shares issued and outstanding, respectively |
|
72
|
|
|
70
|
|
||
Additional paid-in capital
|
|
240,621
|
|
|
238,635
|
|
||
Accumulated other comprehensive income
|
|
267
|
|
|
97
|
|
||
Accumulated deficit
|
|
(144,385
|
)
|
|
(151,827
|
)
|
||
Total stockholders' equity
|
|
96,575
|
|
|
86,975
|
|
||
Total liabilities and stockholders' equity
|
|
$
|
126,409
|
|
|
$
|
130,844
|
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Core companion animal health
|
|
$
|
27,021
|
|
|
$
|
24,464
|
|
|
$
|
51,629
|
|
|
$
|
47,898
|
|
Other vaccines, pharmaceuticals and products
|
|
7,315
|
|
|
5,501
|
|
|
13,089
|
|
|
9,213
|
|
||||
Total revenue, net
|
|
34,336
|
|
|
29,965
|
|
|
64,718
|
|
|
57,111
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
Cost of revenue
|
|
19,407
|
|
|
17,283
|
|
|
36,580
|
|
|
32,987
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
Gross profit
|
|
14,929
|
|
|
12,682
|
|
|
28,138
|
|
|
24,124
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Selling and marketing
|
|
5,993
|
|
|
5,386
|
|
|
12,093
|
|
|
11,005
|
|
||||
Research and development
|
|
445
|
|
|
523
|
|
|
975
|
|
|
1,098
|
|
||||
General and administrative
|
|
3,931
|
|
|
3,217
|
|
|
7,722
|
|
|
6,495
|
|
||||
Total operating expenses
|
|
10,369
|
|
|
9,126
|
|
|
20,790
|
|
|
18,598
|
|
||||
Operating income
|
|
4,560
|
|
|
3,556
|
|
|
7,348
|
|
|
5,526
|
|
||||
Interest and other expense (income), net
|
|
(118
|
)
|
|
34
|
|
|
(180
|
)
|
|
(99
|
)
|
||||
Income before income taxes
|
|
4,678
|
|
|
3,522
|
|
|
7,528
|
|
|
5,625
|
|
||||
Income tax expense:
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Current income tax expense
|
|
10
|
|
|
87
|
|
|
17
|
|
|
161
|
|
||||
Deferred income tax expense
|
|
1,529
|
|
|
693
|
|
|
69
|
|
|
1,275
|
|
||||
Total income tax expense
|
|
1,539
|
|
|
780
|
|
|
86
|
|
|
1,436
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
Net income
|
|
3,139
|
|
|
2,742
|
|
|
7,442
|
|
|
4,189
|
|
||||
Net income (loss) attributable to non-controlling interest
|
|
(194
|
)
|
|
220
|
|
|
(498
|
)
|
|
482
|
|
||||
Net income attributable to Heska Corporation
|
|
$
|
3,333
|
|
|
$
|
2,522
|
|
|
$
|
7,940
|
|
|
$
|
3,707
|
|
|
|
|
|
|
|
|
|
|
||||||||
Basic earnings per share attributable
to Heska Corporation
|
|
$
|
0.47
|
|
|
$
|
0.38
|
|
|
$
|
1.14
|
|
|
$
|
0.56
|
|
Diluted earnings per share attributable
to Heska Corporation
|
|
$
|
0.44
|
|
|
$
|
0.35
|
|
|
$
|
1.05
|
|
|
$
|
0.51
|
|
|
|
|
|
|
|
|
|
|
||||||||
Weighted average outstanding shares used to compute basic earnings per share attributable to Heska Corporation
|
|
7,069
|
|
|
6,695
|
|
|
6,967
|
|
|
6,641
|
|
||||
Weighted average outstanding shares used to compute diluted earnings per share attributable to Heska Corporation
|
|
7,632
|
|
|
7,249
|
|
|
7,570
|
|
|
7,206
|
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
|
|
|
|
|
|
|
|
|
||||||||
Net income
|
|
$
|
3,139
|
|
|
$
|
2,742
|
|
|
$
|
7,442
|
|
|
$
|
4,189
|
|
Other comprehensive income:
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Sale of equity investment
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(90
|
)
|
||||
Foreign currency translation
|
|
114
|
|
|
(47
|
)
|
|
170
|
|
|
42
|
|
||||
Comprehensive income
|
|
3,253
|
|
|
2,695
|
|
|
7,612
|
|
|
4,141
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
Comprehensive income (loss) attributable to non-controlling interest
|
|
(194
|
)
|
|
220
|
|
|
(498
|
)
|
|
482
|
|
||||
Comprehensive income attributable to Heska Corporation
|
|
$
|
3,447
|
|
|
$
|
2,475
|
|
|
$
|
8,110
|
|
|
$
|
3,659
|
|
|
|
Six Months Ended June 30,
|
||||||
|
|
2017
|
|
2016
|
||||
CASH FLOWS FROM OPERATING ACTIVITIES:
|
|
|
|
|
||||
Net income
|
|
$
|
7,442
|
|
|
$
|
4,189
|
|
Adjustments to reconcile net income to cash provided by operating activities:
|
|
|
|
|
|
|
||
Depreciation and amortization
|
|
2,192
|
|
|
2,211
|
|
||
Deferred tax expense
|
|
69
|
|
|
1,275
|
|
||
Stock based compensation
|
|
1,386
|
|
|
1,112
|
|
||
Unrealized benefit on foreign currency translation
|
|
20
|
|
|
(2
|
)
|
||
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
||
Accounts receivable
|
|
6,398
|
|
|
1,764
|
|
||
Inventories
|
|
(5,391
|
)
|
|
(3,691
|
)
|
||
Other current assets
|
|
(567
|
)
|
|
363
|
|
||
Accounts payable
|
|
255
|
|
|
(1,725
|
)
|
||
Accrued liabilities and other
|
|
(1,801
|
)
|
|
(367
|
)
|
||
Other non-current assets
|
|
(3,661
|
)
|
|
(2,889
|
)
|
||
Deferred revenue and other
|
|
(917
|
)
|
|
(1,962
|
)
|
||
Net cash provided by operating activities
|
|
5,425
|
|
|
278
|
|
||
CASH FLOWS FROM INVESTING ACTIVITIES:
|
|
|
|
|
||||
Proceeds from sale of equity investment
|
|
—
|
|
|
115
|
|
||
Purchase of minority interest
|
|
(13,757
|
)
|
|
—
|
|
||
Purchases of property and equipment
|
|
(1,865
|
)
|
|
(1,368
|
)
|
||
Proceeds from disposition of property and equipment
|
|
—
|
|
|
405
|
|
||
Net cash used in investing activities
|
|
(15,622
|
)
|
|
(848
|
)
|
||
CASH FLOWS FROM FINANCING ACTIVITIES:
|
|
|
|
|
||||
Proceeds from issuance of common stock
|
|
1,571
|
|
|
649
|
|
||
Repurchase of equity instruments
|
|
(860
|
)
|
|
—
|
|
||
Distributions to non-controlling interest members
|
|
(954
|
)
|
|
—
|
|
||
Proceeds from line of credit borrowings
|
|
26,051
|
|
|
15,886
|
|
||
Repayments of line of credit borrowings
|
|
(22,690
|
)
|
|
(16,028
|
)
|
||
Repayments of other debt
|
|
(79
|
)
|
|
(180
|
)
|
||
Net cash provided by financing activities
|
|
3,039
|
|
|
327
|
|
||
EFFECT OF EXCHANGE RATE CHANGES ON CASH
|
|
91
|
|
|
22
|
|
||
DECREASE IN CASH AND CASH EQUIVALENTS
|
|
(7,067
|
)
|
|
(221
|
)
|
||
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD
|
|
10,794
|
|
|
6,890
|
|
||
CASH AND CASH EQUIVALENTS, END OF PERIOD
|
|
$
|
3,727
|
|
|
$
|
6,669
|
|
Common stock issued - 175,000 shares
|
$
|
6,347
|
|
Debt assumed
|
1,535
|
|
|
Total fair value of consideration transferred
|
$
|
7,882
|
|
|
|
||
Accounts receivable
|
$
|
222
|
|
Inventories
|
39
|
|
|
Due from Cuattro, LLC
|
963
|
|
|
Property and equipment
|
80
|
|
|
Other tangible assets
|
164
|
|
|
Deferred tax asset
|
56
|
|
|
Intangible assets
|
2,521
|
|
|
Goodwill
|
5,783
|
|
|
Accounts payable
|
(112
|
)
|
|
Deferred tax liability
|
(905
|
)
|
|
Other assumed liabilities
|
(929
|
)
|
|
Total fair value of consideration transferred
|
$
|
7,882
|
|
|
Useful Life
|
|
Amortization Method
|
|
Fair Value
|
Customer relationships
|
6.67
|
|
Straight-line
|
|
$2,521
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Income before income taxes
|
|
$
|
4,678
|
|
|
$
|
3,522
|
|
|
$
|
7,528
|
|
|
$
|
5,625
|
|
Total income tax expense
|
|
1,539
|
|
|
780
|
|
|
86
|
|
|
1,436
|
|
||||
Effective tax rate
|
|
32.9
|
%
|
|
22.1
|
%
|
|
1.1
|
%
|
|
25.5
|
%
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Net income attributable to Heska
|
$
|
3,333
|
|
|
$
|
2,522
|
|
|
$
|
7,940
|
|
|
$
|
3,707
|
|
|
|
|
|
|
|
|
|
||||||||
Basic weighted-average common shares outstanding
|
7,069
|
|
|
6,695
|
|
|
6,967
|
|
|
6,641
|
|
||||
Assumed exercise of dilutive stock options and restricted stock units
|
563
|
|
|
554
|
|
|
603
|
|
565
|
|
|||||
Diluted weighted-average common shares outstanding
|
7,632
|
|
|
7,249
|
|
|
7,570
|
|
|
7,206
|
|
||||
|
|
|
|
|
|
|
|
||||||||
Basic earnings per share attributable to Heska
|
$
|
0.47
|
|
|
$
|
0.38
|
|
|
$
|
1.14
|
|
|
$
|
0.56
|
|
Diluted earnings per share attributable to Heska
|
$
|
0.44
|
|
|
$
|
0.35
|
|
|
$
|
1.05
|
|
|
$
|
0.51
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||
Stock options
|
25
|
|
|
138
|
|
|
132
|
|
|
138
|
|
Carrying amount, December 31, 2016
|
$
|
26,647
|
|
Foreign currency adjustments
|
59
|
|
|
Carrying amount, June 30, 2017
|
$
|
26,706
|
|
|
June 30,
|
|
December 31,
|
||||
|
2017
|
|
2016
|
||||
Gross carrying amount
|
$
|
3,309
|
|
|
$
|
3,309
|
|
Accumulated amortization
|
(1,157
|
)
|
|
(963
|
)
|
||
Net carrying amount
|
$
|
2,152
|
|
|
$
|
2,346
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Amortization expense
|
$
|
97
|
|
|
$
|
34
|
|
|
$
|
194
|
|
|
$
|
37
|
|
|
June 30,
|
|
December 31,
|
||||
|
2017
|
|
2016
|
||||
Land
|
$
|
377
|
|
|
$
|
377
|
|
Building
|
2,868
|
|
|
2,868
|
|
||
Machinery and equipment
|
37,488
|
|
|
36,588
|
|
||
Leasehold and building improvements
|
8,126
|
|
|
7,662
|
|
||
Construction in progress
|
1,869
|
|
|
1,655
|
|
||
|
50,728
|
|
|
49,150
|
|
||
Less accumulated depreciation
|
(34,569
|
)
|
|
(32,569
|
)
|
||
Total property and equipment, net
|
$
|
16,159
|
|
|
$
|
16,581
|
|
|
|
June 30,
|
|
December 31,
|
||||
|
|
2017
|
|
2016
|
||||
Raw materials
|
|
$
|
12,551
|
|
|
$
|
10,807
|
|
Work in process
|
|
4,413
|
|
|
3,820
|
|
||
Finished goods
|
|
10,508
|
|
|
7,087
|
|
||
Allowance for excess or obsolete inventory
|
|
(1,404
|
)
|
|
(1,319
|
)
|
||
Total inventory, net
|
|
$
|
26,068
|
|
|
$
|
20,395
|
|
|
June 30,
2017 |
|
December 31,
2016 |
||||
Accrued payroll and employee benefits
|
$
|
1,457
|
|
|
$
|
2,166
|
|
Accrued property taxes
|
522
|
|
|
748
|
|
||
Accrued purchases
|
—
|
|
|
664
|
|
||
Other
|
2,689
|
|
|
2,891
|
|
||
Total accrued liabilities
|
$
|
4,668
|
|
|
$
|
6,469
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
Risk-free interest rate
|
1.75%
|
|
1.17%
|
|
1.75%
|
|
1.19%
|
Expected lives
|
4.9 years
|
|
4.5 years
|
|
4.9 years
|
|
4.5 years
|
Expected volatility
|
41%
|
|
41%
|
|
41%
|
|
41%
|
Expected dividend yield
|
0%
|
|
0%
|
|
0%
|
|
0%
|
|
Six Months Ended June 30,
|
|
Year Ended
December 31,
|
||||||||||
|
2017
|
|
2016
|
||||||||||
|
Options |
|
Weighted Average Exercise Price
|
|
Options |
|
Weighted Average Exercise Price
|
||||||
Outstanding at beginning of period
|
829,617
|
|
|
$
|
23.203
|
|
|
940,610
|
|
|
$
|
14.163
|
|
Granted at Market
|
24,950
|
|
|
$
|
98.794
|
|
|
129,855
|
|
|
$
|
67.706
|
|
Canceled
|
(3,343
|
)
|
|
$
|
46.181
|
|
|
(463
|
)
|
|
$
|
14.881
|
|
Exercised
|
(144,407
|
)
|
|
$
|
10.657
|
|
|
(240,385
|
)
|
|
$
|
11.886
|
|
Outstanding at end of period
|
706,817
|
|
|
$
|
28.326
|
|
|
829,617
|
|
|
$
|
23.203
|
|
Exercisable at end of period
|
456,476
|
|
|
$
|
15.304
|
|
|
532,703
|
|
|
$
|
12.140
|
|
|
|
Options Outstanding
|
|
Options Exercisable
|
||||||||||||
Exercise Prices
|
|
Number of
Options Outstanding at June 30, 2017 |
|
Weighted
Average
Remaining
Contractual
Life in Years
|
|
Weighted
Average
Exercise
Price
|
|
Number of
Options Exercisable at June 30, 2017 |
|
Weighted
Average
Exercise
Price
|
||||||
$ 4.40 - $ 6.90
|
|
97,973
|
|
|
3.20
|
|
$
|
5.406
|
|
|
97,605
|
|
|
$
|
5.403
|
|
$ 6.91 - $ 7.36
|
|
140,266
|
|
|
6.39
|
|
$
|
7.360
|
|
|
120,875
|
|
|
$
|
7.360
|
|
$ 7.37 - $18.13
|
|
166,553
|
|
|
6.55
|
|
$
|
13.317
|
|
|
130,005
|
|
|
$
|
12.030
|
|
$18.14 - $39.76
|
|
169,201
|
|
|
7.57
|
|
$
|
35.054
|
|
|
94,911
|
|
|
$
|
32.025
|
|
$39.77 - $108.25
|
|
132,824
|
|
|
9.58
|
|
$
|
77.623
|
|
|
13,080
|
|
|
$
|
73.803
|
|
$ 4.40 - $108.25
|
|
706,817
|
|
|
6.87
|
|
$
|
28.326
|
|
|
456,476
|
|
|
$
|
15.304
|
|
|
Three Months Ended
June 30, |
|
Six Months Ended June 30,
|
||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
Risk-free interest rate
|
0.70%
|
|
0.55%
|
|
0.67%
|
|
0.53%
|
Expected lives
|
1.2 years
|
|
1.2 years
|
|
1.2 years
|
|
1.2 years
|
Expected volatility
|
45%
|
|
43%
|
|
45%
|
|
42%
|
Expected dividend yield
|
0%
|
|
0%
|
|
0%
|
|
0%
|
|
Minimum pension liability
|
|
Foreign currency translation
|
|
Total accumulated other comprehensive income
|
||||||
Balances at December 31, 2016
|
$
|
(501
|
)
|
|
$
|
598
|
|
|
$
|
97
|
|
Current period other comprehensive income
|
—
|
|
|
170
|
|
|
170
|
|
|||
Balances at June 30, 2017
|
$
|
(501
|
)
|
|
$
|
768
|
|
|
$
|
267
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Interest income
|
$
|
(43
|
)
|
|
$
|
(30
|
)
|
|
$
|
(81
|
)
|
|
$
|
(63
|
)
|
Interest expense
|
51
|
|
|
38
|
|
|
75
|
|
|
76
|
|
||||
Other expense (income), net
|
(126
|
)
|
|
26
|
|
|
(174
|
)
|
|
(112
|
)
|
||||
Total interest and other expense (income), net
|
$
|
(118
|
)
|
|
$
|
34
|
|
|
$
|
(180
|
)
|
|
$
|
(99
|
)
|
Three Months Ended June 30, 2017
|
|
Core
Companion Animal Health |
|
Other Vaccines, Pharmaceuticals and Products
|
|
Total |
||||||
Total revenue
|
|
$
|
27,021
|
|
|
$
|
7,315
|
|
|
$
|
34,336
|
|
Operating income
|
|
2,581
|
|
|
1,979
|
|
|
4,560
|
|
|||
Income before income taxes
|
|
2,683
|
|
|
1,995
|
|
|
4,678
|
|
|||
Capital purchases
|
|
211
|
|
|
779
|
|
|
990
|
|
|||
Depreciation and amortization
|
|
857
|
|
|
243
|
|
|
1,100
|
|
Three Months Ended June 30, 2016
|
|
Core
Companion Animal Health |
|
Other Vaccines, Pharmaceuticals and Products
|
|
Total |
||||||
Total revenue
|
|
$
|
24,464
|
|
|
$
|
5,501
|
|
|
$
|
29,965
|
|
Operating income
|
|
2,746
|
|
|
810
|
|
|
3,556
|
|
|||
Income before income taxes
|
|
2,724
|
|
|
798
|
|
|
3,522
|
|
|||
Capital purchases
|
|
82
|
|
|
381
|
|
|
463
|
|
|||
Depreciation and amortization
|
|
915
|
|
|
200
|
|
|
1,115
|
|
Six months ended June 30, 2017
|
|
Core
Companion Animal Health |
|
Other Vaccines, Pharmaceuticals and Products
|
|
Total |
||||||
Total revenue
|
|
$
|
51,628
|
|
|
$
|
13,090
|
|
|
$
|
64,718
|
|
Operating income
|
|
3,695
|
|
|
3,653
|
|
|
7,348
|
|
|||
Income before income taxes
|
|
3,897
|
|
|
3,631
|
|
|
7,528
|
|
|||
Capital purchases
|
|
655
|
|
|
1,210
|
|
|
1,865
|
|
|||
Depreciation and amortization
|
|
1,702
|
|
|
490
|
|
|
2,192
|
|
Six months ended June 30, 2016
|
|
Core
Companion Animal Health |
|
Other Vaccines, Pharmaceuticals and Products
|
|
Total |
||||||
Total revenue
|
|
$
|
47,898
|
|
|
$
|
9,213
|
|
|
$
|
57,111
|
|
Operating income
|
|
4,504
|
|
|
1,022
|
|
|
5,526
|
|
|||
Income before income taxes
|
|
4,532
|
|
|
1,093
|
|
|
5,625
|
|
|||
Capital purchases
|
|
479
|
|
|
889
|
|
|
1,368
|
|
|||
Depreciation and amortization
|
|
1,812
|
|
|
399
|
|
|
2,211
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
United States
|
$
|
31,902
|
|
|
$
|
28,371
|
|
|
$
|
59,623
|
|
|
$
|
53,955
|
|
Europe
|
516
|
|
|
605
|
|
|
1,902
|
|
|
1,432
|
|
||||
Canada
|
990
|
|
|
340
|
|
|
1,038
|
|
|
771
|
|
||||
Other International
|
928
|
|
|
649
|
|
|
2,155
|
|
|
953
|
|
||||
Total
|
$
|
34,336
|
|
|
$
|
29,965
|
|
|
$
|
64,718
|
|
|
$
|
57,111
|
|
|
|
Core
Companion
Animal Health
|
|
Other Vaccines, Pharmaceuticals and Products
|
|
Total
|
||||||
Total assets
|
|
$
|
105,655
|
|
|
$
|
20,754
|
|
|
$
|
126,409
|
|
Net assets
|
|
74,041
|
|
|
22,534
|
|
|
96,575
|
|
|
|
Core
Companion
Animal Health
|
|
Other Vaccines, Pharmaceuticals and Products
|
|
Total
|
||||||
Total assets
|
|
$
|
110,995
|
|
|
$
|
19,849
|
|
|
$
|
130,844
|
|
Net assets
|
|
68,072
|
|
|
18,903
|
|
|
86,975
|
|
|
June 30,
|
|
December 31,
|
||||
|
2017
|
|
2016
|
||||
United States
|
$
|
123,908
|
|
|
$
|
127,827
|
|
Europe
|
2,501
|
|
|
3,017
|
|
||
Total
|
$
|
126,409
|
|
|
$
|
130,844
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
Revenue
|
$
|
34,336
|
|
|
$
|
29,965
|
|
|
$
|
64,718
|
|
|
$
|
57,111
|
|
Gross profit
|
14,929
|
|
|
12,682
|
|
|
28,138
|
|
|
24,124
|
|
||||
Operating expenses
|
10,369
|
|
|
9,126
|
|
|
20,790
|
|
|
18,598
|
|
||||
Operating income
|
4,560
|
|
|
3,556
|
|
|
7,348
|
|
|
5,526
|
|
||||
Interest and other expense (income), net
|
(118
|
)
|
|
34
|
|
|
(180
|
)
|
|
(99
|
)
|
||||
Income before income taxes
|
4,678
|
|
|
3,522
|
|
|
7,528
|
|
|
5,625
|
|
||||
Income tax expense
|
1,539
|
|
|
780
|
|
|
86
|
|
|
1,436
|
|
||||
Net income
|
3,139
|
|
|
2,742
|
|
|
7,442
|
|
|
4,189
|
|
||||
Net income (loss) attributable to non-controlling interest
|
(194
|
)
|
|
220
|
|
|
(498
|
)
|
|
482
|
|
||||
Net income attributable to Heska
|
$
|
3,333
|
|
|
$
|
2,522
|
|
|
$
|
7,940
|
|
|
$
|
3,707
|
|
|
Three Months Ended
June 30, |
|
Six Months Ended June 30,
|
||||||||
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||
Revenue
|
100.0
|
%
|
|
100.0
|
%
|
|
100.0
|
%
|
|
100.0
|
%
|
Gross profit
|
43.5
|
%
|
|
42.3
|
%
|
|
43.5
|
%
|
|
42.2
|
%
|
Operating expenses
|
30.2
|
%
|
|
30.5
|
%
|
|
32.1
|
%
|
|
32.6
|
%
|
Operating income
|
13.3
|
%
|
|
11.9
|
%
|
|
11.4
|
%
|
|
9.7
|
%
|
Interest and other expense (income), net
|
(0.3
|
)%
|
|
0.1
|
%
|
|
(0.3
|
)%
|
|
(0.2
|
)%
|
Income before income taxes
|
13.6
|
%
|
|
11.8
|
%
|
|
11.6
|
%
|
|
9.8
|
%
|
Income tax expense
|
4.5
|
%
|
|
2.6
|
%
|
|
0.1
|
%
|
|
2.5
|
%
|
Net income
|
9.1
|
%
|
|
9.2
|
%
|
|
11.5
|
%
|
|
7.3
|
%
|
Net income (loss) attributable to non-controlling interest
|
(0.6
|
)%
|
|
0.7
|
%
|
|
(0.8
|
)%
|
|
0.8
|
%
|
Net income attributable to Heska
|
9.7
|
%
|
|
8.4
|
%
|
|
12.3
|
%
|
|
6.5
|
%
|
|
Six Months Ended June 30,
|
||||||
|
2017
|
|
2016
|
||||
Net cash provided by operating activities
|
$
|
5,425
|
|
|
$
|
278
|
|
Net cash used in investing activities
|
(15,622
|
)
|
|
(848
|
)
|
||
Net cash provided by financing activities
|
3,039
|
|
|
327
|
|
||
Effect of currency translation on cash
|
91
|
|
|
22
|
|
||
Decrease in cash and cash equivalents
|
(7,067
|
)
|
|
(221
|
)
|
||
Cash and cash equivalents, beginning of the period
|
10,794
|
|
|
6,890
|
|
||
Cash and cash equivalents, end of the period
|
$
|
3,727
|
|
|
$
|
6,669
|
|
Item 1A.
|
Risk Factors
|
•
|
Inability to meet minimum obligations.
Current agreements, or agreements we may negotiate in the future, may commit us to certain minimum purchase or other spending obligations. It is possible we will not be able to create the market demand to meet such obligations, which could create a drain on our financial resources and liquidity. Some such agreements may require minimum purchases and/or sales to maintain product rights and we may be significantly harmed if we are unable to meet such requirements and lose product rights.
|
•
|
Loss of exclusivity.
In the case of our blood testing instruments, if we are entitled to non-exclusive access to consumable supplies for a defined period upon expiration of exclusive rights, we may face increased competition from a third party with similar non-exclusive access or our former supplier, which could cause us to lose customers and/or significantly decrease our margins and could significantly affect our financial results. In addition, current agreements, or agreements we may negotiate in the future, with suppliers may require us to meet minimum annual sales levels to maintain our position as the exclusive distributor of these products. We may not meet these minimum sales levels and maintain exclusivity over the distribution and sale of these products. If we are not the exclusive distributor of these products, competition may increase significantly, reducing our revenues and/or decreasing our margins.
|
•
|
Changes in economics.
An underlying change in the economics with a supplier, such as a large price increase or new requirement of large minimum purchase amounts, could have a significant,
|
•
|
The loss of product rights upon expiration or termination of an existing agreement.
Unless we are able to find an alternate supply of a similar product, we would not be able to continue to offer our customers the same breadth of products and our sales and operating results would likely suffer. In the case of an instrument supplier, we could also potentially suffer the loss of sales of consumable supplies, which would be significant in cases where we have built a significant installed base, further harming our sales prospects and opportunities. Even if we were able to find an alternate supply for a product to which we lost rights, we would likely face increased competition from the product whose rights we lost being marketed by a third party or the former supplier and it may take us additional time and expense to gain the necessary approvals and launch an alternative product.
|
•
|
High switching costs.
In our blood testing instrument products, we could face significant competition and lose all or some of the consumable revenues from the installed base of those instruments if we were to switch to a competitive instrument. If we need to change to other commercial manufacturing contractors for certain of our regulated products, additional regulatory licenses or approvals generally must be obtained for these contractors prior to our use. This would require new testing and compliance inspections prior to sale, thus resulting in potential delays. Any new manufacturer would have to be educated in, or develop, substantially equivalent processes necessary for the production of our products. We likely would have to train our sales force, distribution network employees and customer support organization on the new product and spend significant funds marketing the new product to our customer base.
|
•
|
The involuntary or voluntary discontinuation of a product line.
Unless we are able to find an alternate supply of a similar product in this or similar circumstances with any product, we would not be able to continue to offer our customers the same breadth of products and our sales would likely suffer. Even if we are able to identify an alternate supply, it may take us additional time and expense to gain the necessary approvals and launch an alternative product, especially if the product is discontinued unexpectedly.
|
•
|
Inconsistent or inadequate quality control.
We may not be able to control or adequately monitor the quality of products we receive from our suppliers. Poor quality items could damage our reputation with our customers.
|
•
|
Limited capacity or ability to scale capacity.
If market demand for our products increases suddenly, our current suppliers might not be able to fulfill our commercial needs, which would require us to seek new manufacturing arrangements and may result in substantial delays in meeting market demand. If we consistently generate more demand for a product than a given supplier is capable of handling, it could lead to large backorders and potentially lost sales to competitive products that are readily available. This could require us to seek or fund new sources of supply, which may be difficult to find or may require terms that are less advantageous if available at all.
|
•
|
Regulatory risk.
Our manufacturing facility and those of some of our third-party suppliers are subject to ongoing periodic unannounced inspection by regulatory authorities, including the FDA, USDA and other federal, state and foreign agencies for compliance with strictly enforced Good Manufacturing Practices, regulations and similar foreign standards. We do not have control over our suppliers' compliance with these regulations and standards. Regulatory violations could potentially lead to interruptions in supply that could cause us to lose sales to readily available competitive products. If one of our suppliers is unable to provide a raw material or finished product due to regulatory issues, it could have a material adverse financial impact on our business
|
•
|
Developmental delays.
We may experience delays in the scale-up quantities needed for product development that could delay regulatory submissions and commercialization of our products in development, causing us to miss key opportunities.
|
•
|
Limited geographic rights.
We typically do not have global geographic rights to products supplied by third parties. If we were to determine a market opportunity in a geography where we did not have distribution rights and were unable to obtain such rights from the supplier, it might hamper our ability to succeed in such geography and our sales and profits would be lower than they otherwise would have been.
|
•
|
Limited intellectual property rights.
We typically do not have intellectual property rights, or may have to share intellectual property rights, to the products supplied by third parties and any improvements to the manufacturing processes or new manufacturing processes for these products.
|
•
|
sell, transfer, lease or dispose of our assets;
|
•
|
create. incur or assume additional indebtedness;
|
•
|
encumber or permit lines on certain of our assets;
|
•
|
make restricted payments, including paying dividends on, repurchasing or making distributions with respect to our common stock;
|
•
|
make specified investments (including loans and advances);
|
•
|
consolidate, merge, sell or otherwise dispose of all our substantially all of our assets; and
|
•
|
enter into certain transactions.
|
•
|
stock sales by large stockholders or by insiders;
|
•
|
changes in the outlook for our business;
|
•
|
our quarterly operating results, including as compared to expected revenue or earnings and in comparison to historical results;
|
•
|
termination, cancellation or expiration of our third-party supplier relationships;
|
•
|
announcements of technological innovations or new products by our competitors or by us;
|
•
|
litigation;
|
•
|
regulatory developments, including delays in product introductions;
|
•
|
developments or disputes concerning patents or proprietary rights;
|
•
|
availability of our revolving line of credit and compliance with debt covenants;
|
•
|
releases of reports by securities analysts;
|
•
|
economic and other external factors; and
|
•
|
general market conditions.
|
•
|
supply of products from third-party suppliers or termination, cancellation or expiration of such relationships;
|
•
|
competition and pricing pressures from competitive products;
|
•
|
the introduction of new products or services by our competitors or by us;
|
•
|
large customers failing to purchase at historical levels;
|
•
|
fundamental shifts in market demand;
|
•
|
manufacturing delays;
|
•
|
shipment problems;
|
•
|
information technology problems, which may prevent us from conducting our business effectively, or at all, and may also raise our costs;
|
•
|
regulatory and other delays in product development;
|
•
|
product recalls or other issues which may raise our costs;
|
•
|
changes in our reputation and/or market acceptance of our current or new products; and
|
•
|
changes in the mix of products sold.
|
|
Exhibit Number
|
|
Notes
|
|
Description of Document
|
|
3.1
|
|
|
|
Amended and Restated Bylaws of the Registrant, as amended.
|
|
3.2
|
|
|
|
Director Compensation Policy.
|
|
31.1
|
|
|
|
Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.
|
|
31.2
|
|
|
|
Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.
|
|
32.1**
|
|
|
|
Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
101.INS
|
|
|
|
XBRL Instance Document.
|
|
101.SCH
|
|
|
|
XBRL Taxonomy Extension Schema Document.
|
|
101.CAL
|
|
|
|
XBRL Taxonomy Extension Calculation Linkbase Document.
|
|
101.DEF
|
|
|
|
XBRL Taxonomy Extension Definition Linkbase Document.
|
|
101.PRE
|
|
|
|
XBRL Taxonomy Extension Presentation Linkbase Document.
|
|
101.LAB
|
|
|
|
XBRL Taxonomy Extension Label Linkbase Document.
|
Notes
|
|
**
|
Furnished with this report.
|
|
HESKA CORPORATION
|
|
|
|
By:
/s/ KEVIN S. WILSON
Kevin S. Wilson
Chief Executive Officer and President
|
|
By:
/s/ JOHN MCMAHON
John McMahon
Vice President, Chief Financial Officer
|
|
Exhibit Number
|
|
Notes
|
|
Description of Document
|
|
3.1
|
|
|
|
Amended and Restated Bylaws of the Registrant, as amended.
|
|
3.2
|
|
|
|
Director Compensation Policy.
|
|
31.1
|
|
|
|
Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.
|
|
31.2
|
|
|
|
Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.
|
|
32.1**
|
|
|
|
Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
101.INS
|
|
|
|
XBRL Instance Document.
|
|
101.SCH
|
|
|
|
XBRL Taxonomy Extension Schema Document.
|
|
101.CAL
|
|
|
|
XBRL Taxonomy Extension Calculation Linkbase Document.
|
|
101.DEF
|
|
|
|
XBRL Taxonomy Extension Definition Linkbase Document.
|
|
101.PRE
|
|
|
|
XBRL Taxonomy Extension Presentation Linkbase Document.
|
|
101.LAB
|
|
|
|
XBRL Taxonomy Extension Label Linkbase Document.
|
Notes
|
|
**
|
Furnished with this report.
|
Role
|
Service Retainer
|
Chair of the Board
|
$20,000
|
Lead Director
|
$10,000
|
Audit Chair
|
$20,000
|
Compensation Chair
|
$12,000
|
Corporate Governance Chair
|
$7,500
|
Audit Member
|
$10,000
|
Compensation Member
|
$6,000
|
Corporate Governance Member
|
$3,000
|
1.
|
I have reviewed this quarterly report on Form 10-Q of Heska Corporation;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
a.
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b.
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; and
|
c.
|
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d.
|
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
|
5.
|
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
|
a.
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
|
b.
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
|
Dated: August 3, 2017
|
/s/ Kevin S. Wilson
|
|
KEVIN S. WILSON
|
|
Chief Executive Officer and President
|
|
(Principal Executive Officer)
|
1.
|
I have reviewed this quarterly report on Form 10-Q of Heska Corporation;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
a.
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
b.
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; and
|
c.
|
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
d.
|
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
|
5.
|
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
|
a.
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
|
b.
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
|
Dated:
August 3, 2017
|
/s/ John McMahon
|
|
JOHN MCMAHON
|
|
Vice President, Chief Financial Officer
|
|
(Principal Financial Officer)
|
Dated: August 3, 2017
|
By:
|
/s/ Kevin S. Wilson
|
|
Name:
|
KEVIN S. WILSON
|
|
Title:
|
Chief Executive Officer and President
|
Dated: August 3, 2017
|
By:
|
/s/ John McMahon
|
|
Name:
|
JOHN MCMAHON
|
|
Title:
|
Vice President, Chief Financial Officer
|
|
|
|